Loreley Financing (Jersey) No. 4 Ltd. v. UBS Ltd.

42 Misc. 3d 858, 978 N.Y.S.2d 615
New York Supreme Court·Decided December 24, 2013·Published·Cited by 4 cases

Opinion

OPINION OF THE COURT

Shirley Werner Kornreich, J.

Plaintiffs move for reargument and renewal of the court’s order dated April 5, 2013 (the April order), which dismissed the complaint with prejudice. Plaintiffs’ motion is denied for the reasons that follow.

The court assumes familiarity with the April order, which sets forth the facts in detail.1 In short, plaintiffs are special purpose investment vehicles managed by IKB, a German bank well known for having invested its clients’ money in long residential mortgage backed securities (RMBS) positions shortly before the market crashed in 2007 (e.g., IKB also invested its clients’ money in ABACUS, the collateralized debt obligation [CDO] at issue in ACA Fin. Guar. Corp. v Goldman, Sachs & Co. [35 Misc 3d 1217(A), 2012 NY Slip Op 50723(U) (Sup Ct, NY County 2012)], discussed below). In this action, plaintiffs allege that two of the CDOs at issue were Magnetar deals — that is, their collateral was supposedly “designed to fail” by Magnetar.2 Allegedly, Magnetar selected the collateral instead of defendant Declaration Management & Research LLC and nonparty Tricadia CDO Management, LLC, the official collateral managers for Draco 2007-1 and TABS 2007-7 respectively. As for the other two CDOs, plaintiffs alleged they were fraudulently induced to invest in them based on various false statements made by UBS. The court will not repeat the reasons for dismissal set forth in the April order. Rather, the court will only discuss (1) subsequent cases which bolster the original bases for dismissal; (2) loss causation, addressed here in more detail than in the April order; and (3) why emails about a ratings agency [860]*860methodology change does not save the AMP CDO 2007-2 and Cairn Mezz ABS CDO IV fraud claims.

I. Legal Standard

Pursuant to CPLR 2221 (d) (2),

“[a] motion for leave to reargue . . .

“2. shall be based upon matters of fact or law allegedly overlooked or misapprehended by the court in determining the prior motion, but shall not include any matters of fact not offered on the prior motion.” (Mendez v Queens Plumbing Supply, Inc., 39 AD3d 260 [1st Dept 2007].) Pursuant to CPLR 2221 (e), “[a] motion for leave to renew ‘shall be based upon new facts not offered on the prior motion that would change the prior determination,’ and ‘shall contain reasonable justification for the failure to present such facts on the prior motion.’ ” (Queens Unit Venture, LLC v Tyson Ct. Owners Corp., Ill AD3d 552, 552 [1st Dept 2013].) A renewal motion is not “a second chance freely given to parties who have not exercised due diligence in making their first factual presentation.” (Id., quoting Sobin v Tylutki, 59 AD3d 701, 702 [2d Dept 2009].) “The motion . . . [should be] denied ... [if the movant] fail[s] to proffer a reasonable excuse for not presenting the allegedly new facts on the initial motions.” (Illinois Natl. Ins. Co. v Zurich Am. Ins. Co., 107 AD3d 608, 609-610 [1st Dept 2013].)

II. Recent Cases

In the April order, the court felt it important to distinguish this case from the ABACUS cases. ABACUS was a transaction where Goldman Sachs partnered with a monoline insurer, ACA, to sell long RMBS positions through a CDO. The prospective investors were told that ACA, like Declaration, would be an independent collateral manager, whose interests would be aligned with the long investors. However, Goldman and ACA secretly agreed that they would allow another hedge fund, called Paul-son, to actually pick the collateral. ACA agreed to the plan because Goldman told it that Paulson would also be betting long — hence aligning its interest with both ACA and the other investors. In truth, Goldman knew that Paulson was betting short, and did not tell this to ACA. Ultimately, the housing market crashed, Paulson made a killing shorting the market, and ACA and the long investors lost money.3 Lawsuits were filed.

[861]*861This court addressed a decision by another Commercial Division Justice, who denied Goldman’s motion to dismiss ACA’s fraud claim relating to ABACUS, and distinguished it. (See ACA Fin. Guar. Corp. v Goldman, Sachs & Co., 35 Misc 3d 1217[A], 2012 NY Slip Op 50723[U] [Sup Ct, NY County 2012].) Simply put, ACA, at first glance, appeared more egregious than this case.4 In any event, approximately one month after the April order was issued, the Appellate Division reversed the ACA decision, dismissing the case. (ACA Fin. Guar. Corp. v Goldman, Sachs & Co., 106 AD3d 494 [2013].) Thus, it would appear, if ACA is not a viable fraud case, this case is not viable.

Yet, given that there are differences between ACA and this case, the court is guided by another recent, well reasoned and persuasive federal case, which is exactly on point. (See Financial Guar. Ins. Co. v Putnam Advisory Co., 2013 WL 5230818, 2013 US Dist LEXIS 129120 [SD NY, Sept. 10, 2013, Sweet, J., No. 12-Civ-7372 (RWS)].) That case also involved allegations that Magnetar secretly selected a CDO’s collateral. (2013 WL 5230818, *2-3, 2013 US Dist LEXIS 129120, *3-6.) Judge Sweet dismissed that case because “[plaintiff] failed [to] put forth allegations supporting the contention that any part of [plaintiffs] losses were caused by the alleged misrepresentation, rather than external market forces.” (2013 WL 5230818, *3, 2013 US Dist LEXIS 129120, *9.) That is, plaintiff could not plead loss causation.5 Judge Sweet explained:

“[Plaintiff] has contended that it has pled loss causation via its allegation ‘that the very wrong of which it complains — that the . . . collateral was [862]*862selected by a net short investor with interests adverse to long investors — caused the collateral to be far more likely to default than that of a typical CDO, even in the event of market-wide losses.’ However, this allegation is not adequately supported, as [plaintiff] has not buttressed it with facts sufficient to demonstrate that there was any pool of collateral that could have avoided default while still conforming to [the CDO’s] detailed eligibility criteria.
“Since [plaintiff] has not alleged facts sufficient to show that . . . [its losses were caused by] Magnetar [controlling] the . . . collateral selection process— rather than a consequence of the general market downturn that coincided with the default of many other CDOs during the same time period in which [the subject CDO] failed, see, e.g., Nat’l Comm’n on the Causes of the Fin. & Econ. Crisis, The Financial Crisis Inquiry Report: Final Report 148 (2011) (stating that 91% of U.S. CDO securities had been downgraded by the end of 2008), it has failed to plead the loss causation element of its fraud claim.” (2013 WL 5230818, *3, 2013 US Dist LEXIS 129120, *6-8 [citations omitted; emphasis added], citing Len-tell v Merrill Lynch & Co., Inc., 396 F3d 161, 174 [2d Cir 2005] [“(W)hen the plaintiffs loss coincides with a marketwide phenomenon causing comparable losses to other investors ...

Free access — add to your briefcase to read the full text and ask questions with AI

Loreley Financing (Jersey) No. 4 Ltd. v. UBS Ltd., 42 Misc. 3d 858, 978 N.Y.S.2d 615 (N.Y. Super. Ct. 2013).

42 Misc. 3d 858 (Loreley Financing (Jersey) No. 4 Ltd. v. UBS Ltd.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Asinga v. Gatorade Co.
Second Circuit, 2026
Karsch v. Blink Health LTD
S.D. New York, 2022
Honig v. Hansen
S.D. New York, 2021
RamiroAviles v. S&P Global, Inc.
380 F. Supp. 3d 221 (S.D. Illinois, 2019)